Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Part of paid clinical trials in Albuquerque, New Mexico.

Sponsor
Swedish Medical Center
Study ID
NCT00316407
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Ovarian Epithelial Cancer Stage III
  • Stage IV Breast Cancer
  • Stage IV Ovarian Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib (GW572016) — DRUG
    1000 mg po qd
  • Carboplatin — DRUG
    AUC 2 weekly x 3 of 4 week cycle
  • Paclitaxel — DRUG
    60 mg/m2 weekly x 3 of 4 week cycle

Study Details

The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.

Key Dates

Start date
Aug 31, 2005
Status verified
Mar 2010
Primary completion
Nov 30, 2009
Completion
Nov 30, 2009

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Toxicity [ Time Frame: 1 year ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of New Mexico Cancer CenterAlbuquerqueNew Mexico87131-
Swedish Medical Center Cancer InstituteSeattleWashington98104-

Find similar trials in Albuquerque, NM

By research site
University of New Mexico Cancer Center· Albuquerque, NMSwedish Medical Center Cancer Institute· Seattle, WA

Related Studies